Add to ORKGThe present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also prides methods for making the oral arsenic tioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.published_or_final_versio
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferati...
The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferati...
Arsenic trioxide (AS2O3) for leukaemia treatment was described a century ago. Recent resurgence in t...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
INTRODUTION: Arsenic trioxide (As2O3) induces a remission in over 90% of patients with relapsed acut...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferati...
The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferati...
Arsenic trioxide (AS2O3) for leukaemia treatment was described a century ago. Recent resurgence in t...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of in...
INTRODUTION: Arsenic trioxide (As2O3) induces a remission in over 90% of patients with relapsed acut...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...
Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myelo...